Tegafur: Clinical Trials

61 trials of Tegafur, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 unknown, 13 completed, 13 recruiting, 6 terminated. 61 Phase 2, 5 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 261Unknown 25, Completed 13, Recruiting 13, Terminated 6, Not yet recruiting 3, Active not recruiting 1
Phase 35Unknown 2, Completed 1, Recruiting 1, Terminated 1
Phase 11Unknown 1

Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
Ferrous succinate, Ferrous Sulfate, Serplulimab - Gastric Neoplasms
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology542026-09-012026-10-14
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7202026-07-312026-08-14
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma
serplulimab, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2RecruitingNational Cancer Center, Japan1362026-07-152026-11-13
A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens - IB-II Gastric Cancer
Phase 2RecruitingXijing Hospital1202026-07-012026-08-26
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
SOX regimen, CAPEOX regimen, PD-1 inhibitor - Gastric Adenocarcinoma, Stomach Neoplasms
Phase 2RecruitingJinbo Yue542025-10-012026-10-15
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab. - Hepatoid Adenocarcinoma of Stomach
Phase 2RecruitingPeking University Cancer Hospital & Institute302025-09-182025-12-02
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC)
Phase 2RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical University402025-07-232025-09-10
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
Tislelizumab, Anlotinib, Oxaliplatin - Immunotherapy Gastroesophageal Junction
Phase 2UnknownFujian Cancer Hospital282024-08-012024-05-07
Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC
Serplulimab, Trastuzumab, Oxaliplatin + Tegafur - HER2-positive Gastric Cancer
Phase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University422024-07-152024-06-03
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Serplulimab, thymalfasin, Oxaliplatin - Gastric Cancer, Esophagogastric Junction Adenocarcinoma
Phase 2RecruitingZekuan Xu302024-06-142026-03-03
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Tegafur - Esophageal Squamous Cell Carcinoma
Phase 2RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical University452024-05-072024-07-17
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
HR070803, Oxaliplatin, Tegafur - Efficacy and Safety
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University1202024-04-202024-04-25
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Cadonilimab, Ivonescimab, XELOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 2RecruitingHarbin Medical University502024-04-102024-06-27
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Nimotuzumab, Tegafur, radiotherapy - Esophageal Squamous Cell Carcinoma
Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University952024-03-312025-05-25
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Adebrelimab, Apatinib, Tegafur - Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University322024-03-112026-06-04
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2RecruitingSun Yat-sen University1402024-03-012024-03-12
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LM-302, Toripalimab, Capecitabine - Malignant Neoplasms of Digestive Organs
Phase 2RecruitingLaNova Medicines Zhejiang Co., Ltd.6322023-07-272026-10-19
Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
Oxaliplatin, S1, Cetuximab - For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method
Phase 2UnknownLiaoning Cancer Hospital & Institute1002023-03-152023-03-20
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1
Phase 2UnknownMeng Qiu662023-02-202025-01-22
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur - Advanced Biliary Tract Carcinoma
Phase 2Active not recruitingFirst Affiliated Hospital of Zhejiang University302022-11-012026-02-12

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Stomach Neoplasms (14)  ·  Carcinoma, Hepatocellular (4)  ·  Esophageal Squamous Cell Carcinoma (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Colorectal Neoplasms (3)  ·  Adenocarcinoma (2)  ·  Breast Neoplasms (2)  ·  Colonic Neoplasms (2)  ·  Esophageal Neoplasms (2)  ·  Head and Neck Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Adenoma, Islet Cell (1)  ·  Biliary Tract Neoplasms (1)

Sponsors

The First Affiliated Hospital with Nanjing Medical University (3)  ·  Chang Gung Memorial Hospital (2)  ·  Chinese Academy of Medical Sciences (2)  ·  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2)  ·  Fudan University (2)  ·  Fujian Cancer Hospital (2)  ·  National Taiwan University Hospital (2)  ·  Sun Yat-sen University (2)  ·  Aiping Zhou (1)  ·  Anhui Chest Hospital (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Clinical Research Support Center Kyush (1)  ·  Eastern Cooperative Oncology Group (1)  ·  Eastern Hepatobiliary Surgery Hospital (1)  ·  Eastern Network of Cancer Immunological Therapy, Japan (1)

Countries

China (31)  ·  Taiwan (10)  ·  Japan (4)  ·  South Korea (3)  ·  United States (3)  ·  United Kingdom (2)  ·  Egypt (1)  ·  Puerto Rico (1)

Top investigators

Yihebali Chi, doctor (2)  ·  Aiping Zhou (1)  ·  Aiping Zhou, Doctor (1)  ·  Ashraf Abdelaziz, MD/PhD (1)  ·  Bin Wang (1)  ·  Caigang Liu, doctor (1)  ·  Chih-Hung Hsu, M.D. Ph.D. (1)  ·  Chih-Hung Hsu, M.D.Ph.D (1)  ·  Chunmei Bai (1)  ·  Dae Young Zang, MD, PhD (1)  ·  Deliang Fu (1)  ·  Feng Wang (1)  ·  Fuxiang Zhou, M.D. (1)  ·  Haijiao Yan (1)  ·  Haiping Jiang (1)

Results publications

PMID 36188432, PMID 18048821, PMID 19331206, PMID 21183517, PMID 21338641, PMID 26884585, PMID 27913881, PMID 29372461, PMID 32583567, PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 37501640, PMID 40022044, PMID 41749205